At the dawn of 2023, 3T Biosciences and Boehringer Ingelheim (BI) revealed a strategic collaboration and licensing agreement focused on the discovery and development of next-generation cancer therapies focused on high unmet patient needs.
The alliance unites 3T Biosciences’ 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform and Boehringer Ingelheim‘s focus on cancer cell-directed and immune cell-targeting compounds.
“It’s a collaboration based on the strengths of both companies,” said Stefan Scherer, 3T Biosciences CEO, in an interview at the J.P. Morgan Healthcare Conference.
The TRACE discovery platformIn the alliance, Boehringer Ingelheim will contribute patient-derived TCR data to help 3T with target discovery, identifying antigens with its 3T TRACE discovery platform.
Stefan Scherer
The TRACE platform draws from diverse t…